A precalicreína plasmática é unha glicoproteína que participa na activación dependente de superficie da coagulación do sangue, fibrinólise, xeración de cininas e inflamación. Sintetízase no fígado e segrégase ao sangue como unha soa cadea polipeptídica. A precalicreína plasmática convértese en calicreína plasmática pola acción do factor XIIa polo corte dun enlace interno Arg-Ile. A calicreína plasmática, por tanto, está composta por unha cadea pesada e unha lixeira unidas por unha ponte disulfuro. A cadea pesada orixínase a partir do extremo amino terminal do cimóxeno e contén 4 repeticións en tándem de 90 ou 91 aminoácidos. Cada repetición contén unha estrutura peculiar chamada dominio mazá. A cadea pesada é necesaria para a actividade procoagulante dependete de supericie da calicreína plasmática. A cadea lixeira contén o sitio activo ou dominio catalítico do encima e é homóloga da familia da tripsina de serina proteases. A deficiencia en precalicreína plasmática causa unha activación prolongada do tempo de tromboplastina parcial nos pacientes. O empalme alternativo orixina múltiples variantes de transcrición que codifican diferentes isoformas[8]
↑Chung DW, Fujikawa K, McMullen BA, Davie EW (agosto de 1986). "Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats". Biochemistry25 (9): 2410–7. PMID3521732. doi:10.1021/bi00357a017.
↑McRae BJ, Kurachi K, Heimark RL, Fujikawa K, Davie EW, Powers JC (decembro de 1981). "Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates". Biochemistry20 (25): 7196–206. PMID6976185. doi:10.1021/bi00528a022.
↑Seidah NG, Ladenheim R, Mbikay M, Hamelin J, Lutfalla G, Rougeon F, Lazure C, Chrétien M (outubro de 1989). "The cDNA structure of rat plasma kallikrein". DNA8 (8): 563–74. PMID2598771. doi:10.1089/dna.1989.8.563.
↑Tsuda Y, Teno N, Okada Y, Wanaka K, Bohgaki M, Hijikata-Okunomiya A, Okamoto U, Naito T, Okamoto S (novembro de 1989). "Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikrein". Chemical & Pharmaceutical Bulletin37 (11): 3108–11. PMID2534361. doi:10.1248/cpb.37.3108.
↑Page JD, You JL, Harris RB, Colman RW (outubro de 1994). "Localization of the binding site on plasma kallikrein for high-molecular-weight kininogen to both apple 1 and apple 4 domains of the heavy chain". Arch. Biochem. Biophys.314 (1): 159–64. PMID7944388. doi:10.1006/abbi.1994.1424.
↑Herwald H, Jahnen-Dechent W, Alla SA, Hock J, Bouma BN, Müller-Esterl W (xullo de 1993). "Mapping of the high molecular weight kininogen binding site of prekallikrein. Evidence for a discontinuous epitope formed by distinct segments of the prekallikrein heavy chain". J. Biol. Chem.268 (19): 14527–35. PMID7686159. doi:10.1016/S0021-9258(19)85270-5.
↑Renné T, Dedio J, Meijers JC, Chung D, Müller-Esterl W (setembro de 1999). "Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2". J. Biol. Chem.274 (36): 25777–84. PMID10464316. doi:10.1074/jbc.274.36.25777.
Aznar JA, España F, Aznar J, Tascon A, Jimenez C (1978). "Fletcher factor deficiency: report of a new family". Scandinavian Journal of Haematology21 (2): 94–8. PMID694428. doi:10.1111/j.1600-0609.1978.tb02498.x.
Henderson LM, Figueroa CD, Muller-Esterl W, Stain A, Bhoola KD (1993). "Immunovisualisation of plasma prekallikrein and H-kininogen on human neutrophils and in human hepatocytes". Recent Progress on Kinins. Agents Actions Suppl.38. pp. 590–4. ISBN978-3-0348-7323-9. PMID1466300. doi:10.1007/978-3-0348-7321-5_72.
Beaubien G, Rosinski-Chupin I, Mattei MG, Mbikay M, Chrétien M, Seidah NG (1991). "Gene structure and chromosomal localization of plasma kallikrein". Biochemistry30 (6): 1628–35. PMID1993180. doi:10.1021/bi00220a027.
McMullen BA, Fujikawa K, Davie EW (1991). "Location of the disulfide bonds in human plasma prekallikrein: the presence of four novel apple domains in the amino-terminal portion of the molecule". Biochemistry30 (8): 2050–6. PMID1998666. doi:10.1021/bi00222a007.
España F, Berrettini M, Griffin JH (1989). "Purification and characterization of plasma protein C inhibitor". Thromb. Res.55 (3): 369–84. PMID2551064. doi:10.1016/0049-3848(89)90069-8.
Fujikawa K, Chung DW, Hendrickson LE, Davie EW (1986). "Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein". Biochemistry25 (9): 2417–24. PMID3636155. doi:10.1021/bi00357a018.
Page JD, You JL, Harris RB, Colman RW (1994). "Localization of the binding site on plasma kallikrein for high-molecular-weight kininogen to both apple 1 and apple 4 domains of the heavy chain". Arch. Biochem. Biophys.314 (1): 159–64. PMID7944388. doi:10.1006/abbi.1994.1424.
Ciechanowicz A, Bader M, Wagner J, Ganten D (1994). "Extra-hepatic transcription of plasma prekallikrein gene in human and rat tissues". Biochem. Biophys. Res. Commun.197 (3): 1370–6. PMID8280154. doi:10.1006/bbrc.1993.2628.
Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W (1996). "Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor". Biochemistry35 (1): 266–72. PMID8555184. doi:10.1021/bi951501d.
Hermann A, Buchinger P, Somlev B, Rehbock J (1996). "High and low molecular weight kininogen and plasma prekallikrein/plasma kallikrein in villous capillaries of human term placenta". Placenta17 (4): 223–30. PMID8761966. doi:10.1016/S0143-4004(96)90042-9.
Durham SK, Suwanichkul A, Hayes JD, Herington AC, Powell DR, Campbell PG (1999). "The heparin binding domain of insulin-like growth factor binding protein (IGFBP)-3 increases susceptibility of IGFBP-3 to proteolysis". Horm. Metab. Res.31 (2–3): 216–25. PMID10226805. doi:10.1055/s-2007-978722.
Renné T, Dedio J, Meijers JC, Chung D, Müller-Esterl W (1999). "Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2". J. Biol. Chem.274 (36): 25777–84. PMID10464316. doi:10.1074/jbc.274.36.25777.
Cerf M, Raidoo D, Fink E, Fritz H, Bhoola K (2000). "Plasma kallikrein localisation in human blood vessels". Immunopharmacology44 (1–2): 75–80. PMID10604527. doi:10.1016/S0162-3109(99)00112-5.